Equities

Cizzle Biotechnology Holdings PLC

CIZ:LSE

Cizzle Biotechnology Holdings PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)1.74
  • Today's Change0.035 / 2.06%
  • Shares traded786.43k
  • 1 Year change-0.86%
  • Beta--
Data delayed at least 20 minutes, as of Jul 02 2024 15:31 BST.
More ▼

Profile data is unavailable for this security.

About the company

Cizzle Biotechnology Holdings Plc is a United Kingdom-based diagnostics development company. The Company is engaged in the development of a blood test for the early detection of lung cancer. Its prototype test is based on the ability to detect a stable plasma biomarker, a variant of CIZ1 known as CIZ1B. CIZ1 is a cell nuclear protein involved in deoxyribonucleic acid (DNA) replication, and the targeted CIZ1B variant is correlated with early-stage lung cancer. Its prototype confirmative test has been developed to address the false positive rates of computed tomography (CT) scanning. The test is intended to address a clear unmet clinical need, which is early detection of lung cancer, when curative surgical resection is possible.

  • Revenue in GBP (TTM)0.00
  • Net income in GBP-1.72m
  • Incorporated2007
  • Employees67.00
  • Location
    Cizzle Biotechnology Holdings PLC6th Floor, 60 Gracechurch StreetLONDON EC3V 0HRUnited KingdomGBR
  • Phone+44 20 7469 0930Fax+44 23 8123 0382
  • Websitehttps://cizzlebiotechnology.com/
More ▼

Peer analysis

CompanyRevenue (TTM)Net income (TTM)Market capEmployeesMarket Cap /
Employees
ReNeuron Group Plc249.00k-5.07m1.93m34.001.93m34.00
Fusion Antibodies PLC1.58m-2.84m2.91m50.002.91m50.00
IXICO PLC6.00m-1.87m3.45m89.003.45m89.00
TheraCryf PLC396.00k-3.14m3.63m9.003.63m9.00
ValiRx Plc9.60k-2.04m4.17m8.004.17m8.00
Cizzle Biotechnology Holdings PLC0.00-1.72m6.74m67.006.74m67.00
Destiny Pharma PLC0.00-5.66m8.14m19.008.14m19.00
ImmuPharma PLC0.00-2.92m9.04m5.009.04m5.00
Genflow Biosciences PLC0.00-1.63m9.09m5.009.09m5.00
Synairgen plc0.00-8.41m9.41m36.009.41m36.00
Bivictrix Therapeutics PLC0.00-2.55m10.32m12.0010.32m12.00
Data as of Jul 02 2024. Currency figures normalised to Cizzle Biotechnology Holdings PLC's reporting currency: UK Pound GBX

Institutional shareholders

0.01%Per cent of shares held by top holders
HolderShares% Held
Unicorn Asset Management Ltd.as of 31 May 202434.20k0.01%
Data from 31 May 2024 - 31 May 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.